Quick Answer
Enveric Biosciences, Inc. reported Total Revenue of $39.91 million for fiscal year 2019.
Enveric Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$8.77M +8.4% |
-$9.57M +44.6% |
-$17.29M +6.4% |
-$18.47M +62.3% |
-$48.98M -613.5% |
-$6.86M -184.8% |
| Diluted EPS | -$36.24 +84.1% |
-$228.48 -88.4% |
-$121.29 -833.0% |
-$13.00 | — | — |
| Total Assets | $5.10M +65.3% |
$3.08M -28.3% |
$4.30M -78.0% |
$19.55M -26.8% |
$26.72M +552.2% |
$4.10M +3665.9% |
| Cash and Equivalents | — | — | — | — | — | — |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $4.18M +162.3% |
$1.59M -18.6% |
$1.96M -86.7% |
$14.67M -34.2% |
$22.31M +553.1% |
$3.42M +288.5% |
| R&D Expense | $2.78M -2.1% |
$2.84M -60.8% |
$7.25M -9.7% |
$8.03M +67.6% |
$4.79M +2650.9% |
$174.1K |
| Operating Income | -$8.77M +8.9% |
-$9.63M +41.4% |
-$16.45M +40.0% |
-$27.42M +57.6% |
-$64.62M -1050.4% |
-$5.62M -144.6% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 1.06M +1778.8% |
56,501 -69.1% |
182,625 -91.2% |
2.08M +218.8% |
651,921 -93.5% |
10.10M +90.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2020 | $8.48M | -7.3% | +2.8% |
| Revenue (ASC 606) | September 30, 2020 | $8.48M | -7.3% | +2.8% |
| Net Income | September 30, 2025 | -$1.87M | +10.1% | +25.6% |
| Diluted EPS | September 30, 2025 | -$10.81 | +74.9% | -1014.4% |
| Total Assets | September 30, 2025 | $4.36M | -8.9% | +22.9% |
| Cash and Equivalents | September 30, 2020 | $2.84M | +468.4% | +36.0% |
| Long-Term Debt | September 30, 2018 | $1.7K | -99.9% | -99.8% |
| Stockholders Equity | September 30, 2025 | $3.46M | -12.5% | +58.2% |
| R&D Expense | September 30, 2025 | $402.4K | -49.9% | -68.1% |
| Operating Income | September 30, 2025 | -$1.87M | +10.0% | +25.6% |
| Gross Profit | September 30, 2020 | $1.89M | -0.6% | +3.8% |
| Shares Outstanding | September 30, 2025 | 518,296 | -94.2% | -82.9% |
- Enveric Biosciences, Inc. reported Total Revenue of $39.91 million for fiscal year 2019.
- Enveric Biosciences, Inc. showed a decrease of -7.2% in Total Revenue compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Net Income of -$8.77 million for fiscal year 2025.
- Enveric Biosciences, Inc. showed an increase of +8.4% in Net Income compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Diluted EPS of $36.24 per share (loss) for fiscal year 2025.
- Enveric Biosciences, Inc. showed an increase of +84.1% in Diluted EPS compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Total Assets of $5.10 million for fiscal year 2025.
- Enveric Biosciences, Inc. showed an increase of +65.3% in Total Assets compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Cash and Equivalents of $431.4 thousand for fiscal year 2019.
- Enveric Biosciences, Inc. showed a decrease of -68.5% in Cash and Equivalents compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Long-Term Debt of $0.00 for fiscal year 2018.
- Enveric Biosciences, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Stockholders Equity of $4.18 million for fiscal year 2025.
- Enveric Biosciences, Inc. showed an increase of +162.3% in Stockholders Equity compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported R&D Expense of $2.78 million for fiscal year 2025.
- Enveric Biosciences, Inc. showed a decrease of -2.1% in R&D Expense compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Operating Income of -$8.77 million for fiscal year 2025.
- Enveric Biosciences, Inc. showed an increase of +8.9% in Operating Income compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Gross Profit of $8.15 million for fiscal year 2019.
- Enveric Biosciences, Inc. showed a decrease of -9.3% in Gross Profit compared to the prior fiscal year.
- Enveric Biosciences, Inc. reported Shares Outstanding of 1.06 million shares for fiscal year 2025.
- Enveric Biosciences, Inc. showed an increase of +1778.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: